Publications

Export 6373 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L [M] N O P Q R S T U V W X Y Z   [Show ALL]
W
Wang, Z., B. Wang, C. Jiang, H. Xu, and T. Badawy, "Microscopic characterization of isooctane spray in the near field under flash boiling condition", Applied Energy, vol. 180, pp. 598-606, 2016.
Wang, G., A. E. - M. M. El-Sharkawy, and P. A. Bottomley, "Minimum acquisition methods for simultaneously imaging T(1), T(2), and proton density with B(1) correction and no spin-echoes.", Journal of magnetic resonance (San Diego, Calif. : 1997), vol. 242, pp. 243-55, 2014 May. Abstract

The spin lattice (T(1)) and spin-spin (T(2)) relaxation times, along with the proton density (PD) contain almost all of the information that (1)H MRI routinely uses in clinical diagnosis and research, but are seldom imaged directly. Here, three methods for directly imaging T(1), T(2), and PD with the least possible number of acquisitions - three, are presented. All methods utilize long 0° self-refocusing adiabatic pre-pulses instead of spin-echoes to encode the T(2) information prior to a conventional gradient-echo MRI sequence. T(1) information is encoded by varying the flip-angle (FA) in the 'Dual-τ Dual-FA' and 'Four-FA' methods, or the sequence repetition period, TR, in the 'Dual-τ Dual-TR' method. Inhomogeneity in the FA distribution and slice-selection profile are recognized as the main error sources for T(1) measurements. The former is remedied by integrating an extra FA-dependent acquisition into the 'Four-FA' method to provide self-corrected T(1), T(2), PD, and FA in just four acquisitions - again, the minimum possible. Slice profile errors - which manifest as differences between 2D and 3D T(1) measurements, can be addressed by Bloch equation analysis and experimental calibration. All three methods are validated in phantom studies, and the 'Dual-τ Dual-FA' and 'Four-FA' methods are validated in human brain studies using standard partial saturation and spin-echo methods for reference. The new methods offer a minimum-acquisition option for imaging single-component T(1), T(2), and PD. 'Four-FA' performs best overall in accuracy, with high efficiency per unit accuracy vs. existing methods when B(1)-inhomogeneity is appropriately addressed.

Wang, K., L. Zhoua, S. Zhaoc, Z. Cheng, S. Qiua, Y. Lua, Z. Wua, A. H. A. A. Wahabd, and Hongj, "A microfluidic platform for high-purity separating circulating tumor cells at the single-cell level", talanta, vol. 200, pp. 169-176, 2019.
Wang, H., D. A. R. Musa, N. Ahmad, F. M. A. Altalbawy, N. A. Salman, W. M. Khazaal, N. A. A. Salman, M. Abosaooda, N. Nasajpour-Esfahani, M. Hekmatifar, et al., "Molecular dynamics study of the effects of the porosity and initial pressure on phase transition of porous phase change materials", Journal of Energy Storage, vol. 62, pp. 106891-106899, 2023. 5-journal_of_energy_storage_1.pdf
Wang, C., Y. Li, C. Xu, T. Badawy, A. Sahu, and C. Jiang, "Methanol as an octane booster for gasoline fuels", Fuel, vol. 248, pp. 76-84, 2019.
Warda, M., H. K. Kim, N. Kim, K. S. Ko, B. D. Rhee, and J. Han, "A matter of life, death and diseases: mitochondria from a proteomic perspective.", Expert review of proteomics, vol. 10, issue 1, pp. 97-111, 2013 Feb. Abstract

Mitochondria are highly ordered, integrated organelles that energize cellular activities and contribute to programmed death by initiating disciplined apoptotic cascades. This review seeks to clarify our understanding of mitochondrial structural-functional integrity beyond the resolved nuclear genome by unraveling the dynamic mitochondrial proteome and elucidating proteome/genome interplay. The roles of mechanochemical coupling between mitoskeleton and cytoskeleton and crosstalk with other organelles in orchestrating cellular outcomes are explained. The authors also review the modulation of mitochondrial-related oxidative stress on apoptosis and cancer development and the context is applied to interpret pathogenetic events in neurodegenerative disorders and cardiovascular diseases. The accumulated proteomics evidence is used to describe the integral role that mitochondria play and how they influence other intracellular organelles. Possible mitochondrial-targeted therapeutic interventions are also discussed.

Warda, M., H. K. Kim, N. Kim, K. S. Ko, B. D. Rhee, and J. Han, "A matter of life, death and diseases: mitochondria from a proteomic perspective.", Expert review of proteomics, vol. 10, issue 1, pp. 97-111, 2013 Feb. Abstract

Mitochondria are highly ordered, integrated organelles that energize cellular activities and contribute to programmed death by initiating disciplined apoptotic cascades. This review seeks to clarify our understanding of mitochondrial structural-functional integrity beyond the resolved nuclear genome by unraveling the dynamic mitochondrial proteome and elucidating proteome/genome interplay. The roles of mechanochemical coupling between mitoskeleton and cytoskeleton and crosstalk with other organelles in orchestrating cellular outcomes are explained. The authors also review the modulation of mitochondrial-related oxidative stress on apoptosis and cancer development and the context is applied to interpret pathogenetic events in neurodegenerative disorders and cardiovascular diseases. The accumulated proteomics evidence is used to describe the integral role that mitochondria play and how they influence other intracellular organelles. Possible mitochondrial-targeted therapeutic interventions are also discussed.

Wassef, M. A. A., O. M. Tork, L. A. Rashed, W. Ibrahim, H. Morsi, and D. M. M. Rabie, "Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.", Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, vol. 126, issue 1, pp. 27-38, 2018. Abstract

Therapy targeting mitochondria may provide novel ways to treat diabetes and its complications. Bone marrow-derived mesenchymal stem cells (MSCs), the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists and exendin-4; an analog of glucagon-like peptide-1 have shown cardioprotective properties in many cardiac injury models. So, we evaluated their effects in diabetic cardiomyopathy (DCM) in relation to mitochondrial dysfunction. This work included seven groups of adult male albino rats: the control group, the non-treated diabetic group, and the treated diabetic groups: one group was treated with MSCs only, the second with pioglitazone only, the third with MSCs and pioglitazone, the forth with exendin-4 only and the fifth with MSCs and exendin-4. All treatments were started after 6 weeks from induction of diabetes and continued for the next 4 weeks. Blood samples were collected for assessment of glucose, insulin, and cardiac enzymes. Hearts were removed and used for isolated heart studies, and gene expression of: myocyte enhancer factor-2 (), peroxisome proliferator-activated receptor gamma coactivator1-alpha (), nuclear factor kappa B () and autophagic markers: light chain 3 () and beclin by real-time reverse transcription-polymerase chain reaction. The cardiac mitochondrial protein levels of cardiolipin and uncoupler protein 2 (UCP2) were assessed by ELISA and western blot technique, respectively. Treated groups showed significant improvement in left ventricular function associated with improvement in the cardiac injury and myopathic markers compared to the non treated diabetic group. was down-regulated while cardiolipin, , and beclin were up-regulated in all treated groups. These data suggest that the cardioprotective effects of MSCs, exendin-4 or pioglitazone based on their ability to improve mitochondrial functions through targeting inflammatory and autophagy signaling. The co- administration of pioglitazone or exendin-4 with MSCs showed significant superior improvement compared with MSCs alone, indicating the ability to use them in supporting cardioprotective effects of MSCs.

Wassef, M. A. A., O. M. Tork, L. A. Rashed, W. Ibrahim, H. Morsi, and D. M. M. Rabie, "Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.", Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2017 Apr 27. Abstract

Therapy targeting mitochondria may provide novel ways to treat diabetes and its complications. Bone marrow-derived mesenchymal stem cells (MSCs), the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists and exendin-4; an analog of glucagon-like peptide-1 have shown cardioprotective properties in many cardiac injury models. So, we evaluated their effects in diabetic cardiomyopathy (DCM) in relation to mitochondrial dysfunction. This work included seven groups of adult male albino rats: the control group, the non-treated diabetic group, and the treated diabetic groups: one group was treated with MSCs only, the second with pioglitazone only, the third with MSCs and pioglitazone, the forth with exendin-4 only and the fifth with MSCs and exendin-4. All treatments were started after 6 weeks from induction of diabetes and continued for the next 4 weeks. Blood samples were collected for assessment of glucose, insulin, and cardiac enzymes. Hearts were removed and used for isolated heart studies, and gene expression of: myocyte enhancer factor-2 (Mef2), peroxisome proliferator-activated receptor gamma coactivator1-alpha (PGC1α), nuclear factor kappa B (NFKB) and autophagic markers: light chain 3 (LC3) and beclin by real-time reverse transcription-polymerase chain reaction. The cardiac mitochondrial protein levels of cardiolipin and uncoupler protein 2 (UCP2) were assessed by ELISA and western blot technique, respectively. Treated groups showed significant improvement in left ventricular function associated with improvement in the cardiac injury and myopathic markers compared to the non treated diabetic group. NFKB was down-regulated while cardiolipin, PGC1α, LC.3 and beclin were up-regulated in all treated groups. These data suggest that the cardioprotective effects of MSCs, exendin-4 or pioglitazone based on their ability to improve mitochondrial functions through targeting inflammatory and autophagy signaling. The co- administration of pioglitazone or exendin-4 with MSCs showed significant superior improvement compared with MSCs alone, indicating the ability to use them in supporting cardioprotective effects of MSCs.

Wassef, M. A. A., O. L. A. M.TORK, L. A.Rashed, W. Ibrahim, H. Morsi, and D. M. M. Rabie, "Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.,", Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, , vol. Volume 126, issue 1, pp. 27-38, 2018.
Wassef, M. A. A., O. M. Tork, L. A.Rashed, W. I. Ali, H. M. Morsi, and D. M. M. Rabie, Mitochondrial dysfunction in diabetic cardiomyopathy: effect of mesenchymal stem cell with PPAR-γ agonist or exendin-4, , cairo, cairo, 2017. dina_abstract.doc
Wassef, M. A. A., O. M. Tork, L. A. Rashed, W. Ibrahim, H. Morsi, and D. M. M. Rabie, "Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.", Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2017 Apr 27. Abstract

Therapy targeting mitochondria may provide novel ways to treat diabetes and its complications. Bone marrow-derived mesenchymal stem cells (MSCs), the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists and exendin-4; an analog of glucagon-like peptide-1 have shown cardioprotective properties in many cardiac injury models. So, we evaluated their effects in diabetic cardiomyopathy (DCM) in relation to mitochondrial dysfunction. This work included seven groups of adult male albino rats: the control group, the non-treated diabetic group, and the treated diabetic groups: one group was treated with MSCs only, the second with pioglitazone only, the third with MSCs and pioglitazone, the forth with exendin-4 only and the fifth with MSCs and exendin-4. All treatments were started after 6 weeks from induction of diabetes and continued for the next 4 weeks. Blood samples were collected for assessment of glucose, insulin, and cardiac enzymes. Hearts were removed and used for isolated heart studies, and gene expression of: myocyte enhancer factor-2 (Mef2), peroxisome proliferator-activated receptor gamma coactivator1-alpha (PGC1α), nuclear factor kappa B (NFKB) and autophagic markers: light chain 3 (LC3) and beclin by real-time reverse transcription-polymerase chain reaction. The cardiac mitochondrial protein levels of cardiolipin and uncoupler protein 2 (UCP2) were assessed by ELISA and western blot technique, respectively. Treated groups showed significant improvement in left ventricular function associated with improvement in the cardiac injury and myopathic markers compared to the non treated diabetic group. NFKB was down-regulated while cardiolipin, PGC1α, LC.3 and beclin were up-regulated in all treated groups. These data suggest that the cardioprotective effects of MSCs, exendin-4 or pioglitazone based on their ability to improve mitochondrial functions through targeting inflammatory and autophagy signaling. The co- administration of pioglitazone or exendin-4 with MSCs showed significant superior improvement compared with MSCs alone, indicating the ability to use them in supporting cardioprotective effects of MSCs.

Wassef, M. A. A., O. M. Tork, L. A. Rashed, W. Ibrahim, H. Morsi, and D. M. M. Rabie, "Mitochondrial dysfunction in diabetic cardiomyopathy: effect of mesenchymal stem cell with PPAR-γ agonist or exendin-4", Exp Clin Endocrinol Diabetes, vol. 126, issue 1, pp. 27-38, 2017. wassef2017.pdf
Wassif, K., and A. Rafea, "MTL-CKRL as A Knowledge Representation Language for Task Adaptive Learning", 33th Annual Conference on Statistics, Computer Sciences and Operation Researchs, 1998.
WEBB, M. A. R. I. A. L., and M. M. Mashaly, "Maturation of the diurnal rhythm of corticosterone in female domestic fowl", Poultry science, vol. 64, issue 4: Poultry Science Association, pp. 744-750, 1985. Abstract
n/a
Welson, M. M., D. G. Amin, and E. H. Elnoshokaty, "Molecular detection of 6q deletion in Egyptian patients with B-cell chronic lymphoproliferative disorders ", Egyptian Journal of Haematology , vol. 37, pp. 129–134, 2012.
Wiens, K. E., P. A. Lindstedt, B. F. Blacker, K. B. Johnson, M. M. Baumann, L. E. Schaeffer, H. Abbastabar, F. Abd-Allah, A. Abdelalim, I. Abdollahpour, et al., "Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17", The Lancet Global Health, vol. 8, no. 8: Elsevier, pp. e1038–e1060, 2020. Abstract
n/a
Wifi, A. S., and Y. Yamada, "ment, Faculty of EnglnzesUng, Caino Univzutiiy, Cavio, Egypt.** Pnofu&on, ImtUute of Induitnlal Science, Univzuity of Tokyo, Roppong-c, Tokyo, Japan.", Current advances in mechanical design and production: proceedings of the 1st international conference, Cairo University, Egypt, 27-29 December 1979: Pergamon, pp. 229, 1981. Abstract
n/a
Wissam, F., P. Szabó, M. S. A. EL-Kader, and M. Gustafsson, "Molecular dynamics calculations of collision-induced absorption in a gas mixture of neon and krypton", Journal of Chemical physics, vol. 152, pp. 234302, 2020.
Wong, B. J. F., T. E. Milner, B. Anvari, A. Sviridov, A. Omel'chenko, V. V. Bagratashvili, E. Sobol, and J. S. Nelson, "Measurement of radiometric surface temperature and integrated backscattered light intensity during feedback-controlled laser-assisted cartilage reshaping", Lasers in Medical Science, vol. 13, issue 1: Springer-Verlag, pp. 66-72, 1998. Abstract
n/a
work, my art work 2020, , cairo, opra house, pp. q, 2020. paint01.jpg
work, my art work 2020, , cairo, opra house, pp. q, 2020. paint01.jpg
Wright, N. J., A. J. M. Leather, N. Ade-Ajayi, N. Sevdalis, J. Davies, D. Poenaru, E. Ameh, A. Ademuyiwa, K. Lakhoo, E. R. Smith, et al., "Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study", The Lancet, vol. 398, no. 10297, pp. 325-339, 2021. AbstractWebsite

{Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung's disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung's disease) from 264 hospitals (89 in high-income countries, 166 in middle-income countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in low-income countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40]

Wright, N. J., A. J. M. Leather, N. Ade-Ajayi, N. Sevdalis, J. Davies, D. Poenaru, E. Ameh, A. Ademuyiwa, K. Lakhoo, E. R. Smith, et al., Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study, , vol. 398, issue 10297, pp. 325 - 339, 2021. AbstractWebsite

SummaryBackground
Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality.
Methods
We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung's disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis.
Findings
We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung's disease) from 264 hospitals (89 in high-income countries, 166 in middle-income countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in low-income countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality.
Interpretation
Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between low-income, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030.
Funding
Wellcome Trust.

Wu, B., F. Tian, M. Nabil, J. Bofana, Y. Lu, A. Elnashar, A. N. Beyene, M. Zhang, H. Zeng, and W. Zhu, "Mapping global maximum irrigation extent at 30m resolution using the irrigation performances under drought stress", Global Environmental Change, vol. 79, pp. 102652, 2023. AbstractWebsite

Accurate global irrigation information is essential for managing water scarcity and improving food security. However, the mapping of high-resolution irrigation at the global scale is challenging due to the wide range of climate conditions, crop types and phenology, ambiguous and heterogeneous spectral features, and farming practices. Here, a robust method is proposed using irrigation performance under drought stress as a proxy for crop productivity stabilization and crop water consumption. For each irrigation mapping zone (IMZ), dry months in the 2017–2019 period and the driest months in the 2010–2019 period were identified over the growing season. The thresholds of the normalized difference vegetation index (NDVI) in the dry months from 2017 to 2019 and the NDVI deviation (NDVIdev) in the driest month were identified to separate irrigated and rainfed cropland with samples. The final threshold from either the NDVI or the NDVIdev of the IMZ was determined with a higher overall accuracy in separating irrigated and non-irrigated areas. The results show that the global maximum irrigation extent (GMIE) at a 30-m resolution was 23.38% of global cropland in 2010–2019, with an overall accuracy of 83.6% globally and significant regional differences in irrigation proportions ranging from 1.1% in western Africa to 100% in Old World deserts among the 110 IMZs and from 0.4% in Belarus to 80.2% in Pakistan and 100% in Egypt among 45 countries. The study quantitatively distinguished annually and intermittently irrigated regions, which had values of 42% and 58% of global cropland, respectively, by applying indicators. This method, using the NDVI and NDVIdev thresholds, is simple, concrete and reproducible and better for zones with homogeneous weather conditions. The study offers independent, consistent and comparable information for defining the baseline, tracking changes in irrigation infrastructure, and leading future changes in how stakeholders plan and design irrigation systems.

Tourism